566
Views
42
CrossRef citations to date
0
Altmetric
Reviews

Differential pricing of new pharmaceuticals in lower income European countries

, &
Pages 735-741 | Published online: 09 Jan 2014

References

  • Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 302(13), 1437–1443 (2009).
  • Drummond M, Jönsson B, Rutten F, Stargardt T. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. Eur. J. Health Econ. 12, 263–271 (2011).
  • Godman B, Gustafsson LL. A new reimbursement systems for innovative pharmaceuticals combining value-based and free market pricing. Appl. Health Econ. Health Policy 11, 79–82 (2013).
  • Annemans L, Cleemput I, Hulstaert F, Simoens S. Valorising and creating access to innovative medicines in the European Union. Front. Pharmacol. 2(57), 1–6 (2011).
  • Kanavos P, Vandoros S, Irwin R, Nicod E, Casson M. Differences in costs of and access to pharmaceutical products in the EU. Directorate general for internal policies, policy department A: Economic and scientific policy. European Parliament, Brussels, Belgium (2011).
  • Garrison LP, Mansley EC, Abbott TA, Bresnahan BW, Hay JW, Smeeding J. Good research practices in cost-effectiveness analyses: a societal perspective: the ISPOR drug cost task force report—part II. Value Health 13(1), 8–13 (2010).
  • Ramsey FP. A contribution to the theory of taxation. Econ. J. 37, 47–61 (1927).
  • Hay JW, Smeeding J, Carroll NV et al. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR drug cost task force report—part I. Value Health 13(1), 3–7 (2010).
  • Danzon PM. Making sense of drug prices. Regulation 23(1), 56–63 (2000).
  • OECD Health Policy Studies. Pharmaceutical Pricing Policies in a Global Market. OECD Publishing, Paris, France (2008).
  • Vogler S, Habl C, Leopold C et al. Vienna, PPRI Report. Gesundheit österreich GmbH / Geschäftsbereich öBIG, Vienna (2008).
  • Ridley DB. Price differentiation and transparency in the global pharmaceutical marketplace. Pharmacoeconomics 23(7), 651–658 (2005).
  • Kaló Z, Docteur E, Moïse P. Pharmaceutical Pricing and Reimbursement Policies in Slovakia, OECD Health Working Paper, No. 31, p.14. OECD, Paris (2008).
  • Ridley DB, Grabowski HG, Moe JL. Developing drugs for developing countries. Health Affairs 25(2), 313–324 (2006).
  • Danzon PM. Price discrimination for pharmaceuticals: welfare effects in the US and the EU. Int. J. Econ. Bus. 4(3), 301–321 (1997).
  • Carlson JJ, Garrison LP, Sullivan SD. Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals. J. Manag. Care Pharm. 15(8), 683–687 (2009).
  • Towse A, Garrison LP. Can’t get no satisfaction? will pay for performance help? toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics 28(2), 93–102 (2010).
  • Coulton L, Annemans L, Carter R et al. Outcomes-based risk-sharing schemes – is there a potential role in the Asia-Pacific markets? Health Outcomes Res. Med. (3)4, e205-e219 (2012).
  • Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 96(3), 179–190 (2010).
  • Kaló Z, Vokó Z. The role of risk sharing in drug funding (in Hungarian). LAM 20(3–4), 237–241 (2010).
  • Orlewska E. Challenges and changes in the polish healthcare system. Soc. Econ. 33(3) 575–594 (2011).
  • Garau M, Towse A, Danzon P. Pharmaceutical pricing in Europe: is differential pricing a win-win solution? occasional paper 11/01, office of health economics, London (2011).
  • Danzon PM, Towse A. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int. J. Health Care Finance Econ. 3(3), 183–205 (2003).
  • Danzon PM, Towse A, Mulcahy AW: Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries. Health Aff. 30(3), 1529–1538 (2011).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.